Amidino dervatives useful as nitric oxide synthase inhibitors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514183, 514210, 514211, 514218, 5142272, 5142288, 514256, 514329, 514370, 514377, 514386, 514426, 540467, 540470, 540480, 540481, 540482, 540544, 540553, 540596, 540598, 540601, 540602, 540603, 540604, 540605, 540606, C07D26706, C07D28102

Patent

active

058542345

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

The present invention relates to amidino derivatives, pharmaceutical compositions containing amidino derivatives, and to their use in therapy, in particular their use as nitric oxide synthase inhibitors.


RELATED ART

It has been known since the early 1980's that the vascular relaxation brought about by acetycholine is dependent on the presence of the endothelium and this activity was ascribed to a labile humoral factor termed endothelium-derived relaxing factor (EDRF). The activity of nitric oxide (NO) as a vasodilator has been known for well over 100 years and NO is the active component of amylnitrite, glyceryltrinitrite and other nitrovasodilators. The recent identification of EDRF as NO has coincided with the discovery of a biochemical pathway by which NO is synthesized from the amino acid L-arginine by the enzyme NO synthase.
NO is the endogenous stimulator of the soluble guanylate cyclase and is involved in a number of biological actions in addition to endothelium-dependent relaxation including cytotoxicity of phagocytic cells and cell-to-cell communication in the central nervous system (see Moncada et al, Biochemical Pharmacology, 38, 1709-1715 (1989) and Moncada et al, Pharmacological Reviews, 43, 109-142 (1991). It is now thought that excess NO production may be involved in a number of conditions, particularly conditions which involve systemic hypotension such as toxic shock and therapy with certain cytokines.
The synthesis of NO from L-arginine can be inhibited by the L-arginine analogue, L-N-monomethyl-arginine (L-NMMA) and the therapeutic use of L-NMMA for the treatment of toxic shock and other types of systemic hypertension has been proposed (WO 91/04024 and GB-A-2240041). The therapeutic use of certain other NO synthase inhibitors apart from L-NMMA for the same purpose has also been proposed in WO 91/04024 and in EP-A-0446699.
It has recently become apparent that there are at least three types of NO synthase as follows: endothelium, that releases NO in response to receptor or physical stimulation. brain, that releases NO in response to receptor or physical stimulation. vascular smooth muscle, macrophages, endothelial cells, and a number of other cells by endotoxin and cytokines. Once expressed this inducible NO synthase synthesizes NO for long periods.
The NO released by the constitutive enzymes acts as a transduction mechanism underlying several physiological responses. The NO produced by the inducible enzyme is a cytotoxic molecule for tumor cells and invading microorganisms. It also appears that the adverse effects of excess NO production, in particular pathological vasodilation and tissue damage, may result largely from the effects of NO synthesized by the inducible NO synthase.
There is also a growing body of evidence that NO may be involved in the degeneration of cartilage which takes place in certain conditions such as arthritis and it is also known that NO synthesis is increased in rheumatoid arthritis. Accordingly, further conditions in which there is an advantage in inhibiting NO production from L-arginine include autoimmune and/or inflammatory conditions affecting the joints, for example arthritis.
Conditions in which there is an advantage in inhibiting NO production from L-arginine include systemic hypotension associated with septic and/or toxic shock induced by a wide variety of agents; therapy with cytokines such as TNF, IL-1 and IL-2; and as an adjuvant to short term immunosuppression in transplant therapy. Further conditions in which there is an advantage in inhibiting NO production from L-arginine include autoimmune diseases and/or inflammatory conditions such as those affecting the joints, for example arthritis or inflammatory bowel disease, cardiovascular ischemia, diabetes, hyperalgesia (allodynia) cerebral ischemia (Both focal ischemia, thrombotic stroke and global ischemia, secondary to cardiac arrest) and other CNS disorders mediated by NO.
Some of the NO synthase inhibitors proposed for therapeutic use so far, and in particular L-NMMA, are non-

REFERENCES:
patent: 2049582 (1936-08-01), Ziegler
patent: 3109848 (1963-11-01), Bortnick et al.
patent: 3121093 (1964-02-01), Bortnick et al.
patent: 3132151 (1964-05-01), Bortnick et al.
patent: 3501487 (1970-03-01), Poos
patent: 3563994 (1971-02-01), Wollweber et al.
patent: 3694432 (1972-09-01), Hershenson
patent: 3725435 (1973-04-01), Poos
patent: 3816457 (1974-06-01), Grisar et al.
patent: 4046909 (1977-09-01), Rasmussen et al.
patent: 4061746 (1977-12-01), Blohm et al.
patent: 4126613 (1978-11-01), Grisar et al.
patent: 4126621 (1978-11-01), Grisar et al.
patent: 4153235 (1979-05-01), Grisar et al.
patent: 4443468 (1984-04-01), Maillard et al.
patent: 4523020 (1985-06-01), Moormann et al.
patent: 4525476 (1985-06-01), Butler et al.
patent: 4533739 (1985-08-01), Pitzele et al.
patent: 4556674 (1985-12-01), Maillard et al.
patent: 4579951 (1986-04-01), Pitzele et al.
patent: 4699918 (1987-10-01), Maillard et al.
patent: 4855444 (1989-08-01), Wambach
patent: 4962204 (1990-10-01), Wambach
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5051444 (1991-09-01), Tamoto et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5081148 (1992-01-01), Braquet et al.
patent: 5132453 (1992-07-01), Griffith
patent: 5196439 (1993-03-01), Sugimoto et al.
patent: 5216025 (1993-06-01), Gross et al.
patent: 5246971 (1993-09-01), Williamson et al.
patent: 5266594 (1993-11-01), Dawson et al.
patent: 5273875 (1993-12-01), Griffith
patent: 5621004 (1997-04-01), Dunn et al.
patent: 5629322 (1997-05-01), Guthikonda et al.
Bertolini et al., "Nitric Oxide Synthase Inhibitors: Recent Advances," Cardiovascular & Renal Patent Update, Ashley Publications Ltd., pp. 1339-1345, 1994.
Culvenor, C.C.J. et al, Aust. J. Chem., 24 (1971) 371-375 (Beilstein Registry ID Only).
Caujolle, R. et al, Eur. J. Med. Chem. Chim. Ther., 28(1) (1993) 29-35 (Beilstein Registry ID Only).
Kato et al, Chem. Pharm. Bull., 20 (1972) 901 (Beilstein Registry ID Only).
Anderson, Wayne K. et al, Synth. Commun., 19(13-14) (1989) 2237-2242 (Beilstein Registry ID Only).
Olomucki et al, Biochim. Biophys. Acta, 263 (1972) 213, 215, 216 (Beilstein Registry ID Only).
Otake, N. et al, Tetrahedron Lett., 19 (1965) 1411-1419 (Beilstein Registry ID Only, .
Patent: Kerin Seiyaku Kabushiki Kaisya, JP, A, 17189, 1968; Referati vnyi Zhurnal. Khimiya., 1(1970) N469P (Beilstein Registry ID Only).
Unezawa et al, J. Antibiot., 26(1973) 625,637 (Beilstein Registry ID Only).
Marconi et al, J. Antibiot., 23 (1970) 120, 121, 122, 123 (Beilstein Registry ID Only).
Kretow et al, J. Gen Chem. USSR, 32 (1962) 464 (Beilstein Registry ID Only).
Dorn et al, Chem. Ber., 103 (1970) 2505, 2506, 2508, 2511 (Beilstein Registry ID Only).
Andrewes et al, Proc. R. Soc. London B, 133 (1946) 20, 53 (Beilstein Registry ID Only).
Schubert, H. W. et al, Arch. Pharm. Ber. Dtsch. Pharm. Ges., 301(10) (1968) 750-762 (Beilstein Registry ID Only).
Stefanye et al, J. Amer. Chem. Soc., 77 (1955) 761 (Beilstein Registry ID Only).
Goodman et al, J. Org. Chem., 23 (1958) 1954, 1956 (Beilstein Registry ID Only).
Goodman et al, J. Org. Chem., 23 (1958) 1251, 1252, 1255, 1954, 1956 (Beilstein Registry ID Only).
Perrin et al., "Absence of Steroelectronic Control in Hydrolysis of Cyclic Amidines", J. Am. Chem. Soc., vol. 108, No. 19, pp. 5997-6003, 1986.
Huber et al., "Saturated Heterocycles, Part 88. Synthesis of a New Ring Perkin Trans. 1, pp. 909-912, 1987.
Kokosi et al., "Nitrogen Bridgehead Compounds, Part 19(1). Synthesis of Polymethylenepyrimidin-4-ones", J. Heterocyclic Chem., vol. 19, pp. 909-912, 1982.
Brown et al., Hydropyrimidines, Part II, pp. 4041-4045, 1962.
Adcock et al., 2-Amino-2-imidazolines 2-Amino-2-oxazolines, Part II, pp. 474-479, 1965.
Stefanye et al., "Cyclic Guanidines from Nitrimino Coumpounds", J. Am. Chem. Soc., vol. 77, No. 3, pp. 761-762, 1955.
Klayman et al., "2-Amino-2-thiazoline. VII. Unequivocal Structure Assignment of the Products of the Reaction of 2-Amino-2-thiazoline and Its Analogs with Carbethoxy Isothiocyanate", J. Org. Chem.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Amidino dervatives useful as nitric oxide synthase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amidino dervatives useful as nitric oxide synthase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amidino dervatives useful as nitric oxide synthase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1424993

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.